Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population

References

• Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581–90.
   Google Scholar
• Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the bio-logical activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882–91.
   Google Scholar
• Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castel-lani LW, Furlong CE, Costa LG, Fogelman AM, Lusis Al Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284–7.
   Google Scholar
• Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase knock-out/apolipoproteine knockout mice exhibit increased lipopro-tein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527–35.
   Google Scholar
• Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484–90.
   Google Scholar
• She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, Liu G, Zhang R, Liu JJ, Stallcup WB, Thou Z, Liu DP, Liang CC. Human paraoxonase gene cluster transgenic overexpres-sion represses atherogenesis and promotes atherosclerotic plaque stability in apoe-null mice. Circ Res 2009; 104: 1160–8.
   Google Scholar
• Mackness B, Mackness MI, Arrol S, Turkic W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modi-fication. FEBS Lett 1998; 423: 57–60.
   Google Scholar
• Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229–35.
   Google Scholar
• James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2252–7.
   Google Scholar
• Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU. Paraoxonase 192 gln/arg gene polymor-phism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 48: 623–7.
   Google Scholar
• Rozenberg 0, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (ponl) deficiency is associated with increased macrophage oxidative stress: Studies in ponl-knockout mice. Free Radic Biol Med 2003; 34: 774–84.
   Google Scholar
• Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152–4.
   Google Scholar
• Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular dis-ease. Curr Opin Lipidol 2004; 15: 399–404.
   Google Scholar
• Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type ii diabetes mellitus complicated by retinopathy. Gun Sci (Lond) 2000; 98: 355–63.
   Google Scholar
• Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-depen-dent diabetes mellitus. Atherosclerosis 1991; 86: 193–9.
   Google Scholar
• Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067–73.
   Google Scholar
• Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Athero-sclerosis 2000; 149: 435–42.
   Google Scholar
• Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS. The gln-arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among chinese in taiwan. Atherosclerosis 1998; 141: 259–64.
   Google Scholar
• Ansell BJ. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 2007; 100: n3–9.
   Google Scholar
• Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, Hui R, Yao Z, Shen Y, Qiang B, Gu D. Extensive association analy-sis between polymorphisms of pon gene cluster with coro-nary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 2003; 23: 328–34.
   Google Scholar
• Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE. Human paraoxonase gene cluster polymorphisms as pre-dictors of coronary heart disease risk in the prospective northwick park heart study ii. Biochim Biophys Acta 2003; 1639: 203–12.
   Google Scholar
• Tomas M, Elosua R, Senti M, Molina L, Vila J, Anglada R, Fito M, Covas MI, Marrugat J. Paraoxonase 1-192 poly-morphism modulates the effects of regular and acute exer-cise on paraoxonasel activity. J Lipid Res 2002; 43: 713–20.
   Google Scholar
• Gouedard C, Koum-Besson N, Barouki R, Morel Y. Oppo-site regulation of the human paraoxonase-1 gene pon-1 by fenofibrate and statins. Mol Pharmacol 2003; 63: 945–56.
   Google Scholar
• Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (pparalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (pon 1) activity. J Physiol Pharmacol 2002; 53: 463–75.
   Google Scholar
• Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: Meta-analysis of 43 studies. Lancet 2004; 363: 689–95.
   Google Scholar
• Mackness M, Mackness B. Paraoxonase 1 and atherosclero-sis. Is the gene or the protein more important? Free Radic Biol Med 2004; 37: 1317–23.
   Google Scholar
• Shin BS. Paraoxonase gene polymorphism in south-western Korean population. J Korean Med Sci 2009; 24: 561–6.
   Google Scholar
• Odawara M, Tachi Y, Yamashita K. Paraoxonase polymor-phism (g1n192-arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257–60.
   Google Scholar
• Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI, Mackness B. Paraoxonase 1 status in the Thai population. J Hum Genet 2005; 50: 293–300.
   Google Scholar
• Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Esti-mating low-density lipoprotein cholesterol by the Friedewaldequation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990; 36: 15–9.
   Google Scholar
• Rea IM, McKeown PP, McMaster D, Young IS, Patterson C, Savage MJ, Belton C, Marchegiani F, Olivieri F, Bonafe M, Franceschi C. Paraoxonase polymorphisms ponl 192 and 55 and longevity in Italian centenarians and Irish nona-genarians. A pooled analysis. Exp Gerontol 2004; 39: 629–35.
   Google Scholar
• Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, Castaldo M, Bonaiuto A, Saitta C, Bitto A, Manduca B, Riggio S, Saitta A. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 2004; 39: 1089–94.
   Google Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473–80.
   Google Scholar
• Rozenberg 0, Shih DM, Aviram M. Human serum paraox-onase 1 decreases macrophage cholesterol biosynthesis: Possible role for its phospholipase-a2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461–7.
   Google Scholar
• Chambers JE. Ponl multitasks to protect health. Proc Natl Acad Sci USA 2008; 105: 12639–40.
   Google Scholar
• Serrato M, Marian AJ. A variant of human paraoxonase/ arylesterase (humpona) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005–8.
   Google Scholar
• Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-argl 92 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869–72.
   Google Scholar
• Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (ponl) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299: 1265–76.
   Google Scholar
• Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (ponl) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 371–92.
   Google Scholar
• Senti M, Aubo C, Tomas M. Differential effects of smoking on myocardial infarction risk according to the gln/arg 192 variants of the human paraoxonase gene. Metabolism 2000; 49: 557–9.
   Google Scholar
• Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraox-onase activity in the serum and hepatic mrna levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307–15.
   Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory hdl becomes pro-inflamma-tory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758–67.
   Google Scholar
• Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circula-tion 2003; 107: 2775–9.
   Google Scholar
• Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, van der Graaf Y Paraoxonase variants relate to 10-year risk in coronary artery disease: Impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 2009; 54: 1238–45.
   Google Scholar
• Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifiesthe effect of statins on paraoxonase activity and lipid para-meters. Br J Clin Pharmacol 2008; 66: 366–74.
   Google Scholar
• Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery dis-ease. OM Biochem 2001; 34: 475–81.
   Google Scholar
• Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tah-vanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J OM Invest 1996; 98: 883–5.
   Google Scholar